Pharma & Biotech Valuation
- Tom Bird
- Dec 10, 2019
- 1 min read
The purpose of this study is to provide corporate finance professionals, managers, and investors, an overview of valuation fundamentals employed in today’s pharmaceutical and biotech communities. These findings are relevant to understanding the values assigned by parties in negotiations for the acquisition or licensing of drug development programs and the approach in determining value.
This study is part of Gryphon Analytics’ public outreach program aimed at collecting and disseminating information about the important role that life sciences venture investing plays in driving revolutionary medical innovation.
Recent Posts
See All
Dominant longer-term investment themes for healthcare investors will be true innovation or cost-control. Successful business models...
Comments